NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









TreeFrog Therapeutics

TreeFrog Therapeutics

Private
PessacHealthcare & Life Scienceshttps://treefrog.fr/

Last Round

Debt

May 27, 2025

Total Funding Raised

$119.94M

Company Overview

TreeFrog Therapeutics is a biotechnology company that develops a proprietary technology platform for the mass production and differentiation of stem cells to enable safe and affordable cell therapies.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Biotech Equipment, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Data as a Service, Services & Consulting

AI Layer

Non-AI

Keywords

cell therapyinduced pluripotent stem celliPSCbioprocessing3D cell culturebioreactorregenerative medicinecell manufacturingbiotech manufacturingCDMOcontract manufacturingcell scale-upbiotech platformbioprocess engineeringstem cell tech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

TreeFrog Therapeutics Comparables

Compare TreeFrog Therapeutics with similar companies based on industry and business-model similarity.

TreeFrog Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
PBS Biotech
77%
Cellevate AB
76%
Cynata Therapeutics Limited
73%

TreeFrog Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
DebtMay 27, 2025
Corporate FundingApr 23, 2024
Series BSep 13, 2021
GrantSep 5, 2019
Series AMay 13, 2019
Grant
Mar 1, 2019

Key People

Founding team and executive leadership

Kévin Alessandri

VP US, Co-founder, CTO

Founding Team

Frédéric Desdouits

Chief Executive Officer

Executive Team

Maxime Feyeux

President, Chief Scientific Officer, CEO CSO

Executive Team

EMBA Michael Lanero Fidalgo

Chief Operating Officer

Executive Team

TreeFrog Therapeutics Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Oct 1, 2025

    Stem cell encapsulator moves from R&D to GMP manufacturing.

  • Oct 1, 2025

    Collaborating with Vertex Pharmaceuticals on C-STEM technology for diabetes treatment.

TreeFrog Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

TreeFrog Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about TreeFrog Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersPessac
Employee Range161
Year Founded2018
Last FundingMay 27, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.